News | Biogen

April 28, 2021

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its supplemental Biologic License Application (sBLA) for a new subcutaneous (SC) route of

April 28, 2021

Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics

April 22, 2021

Biogen Reports First Quarter 2021 Results

Grid View List View

November 18, 2020

Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)

INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application for SB11, a proposed biosimilar

November 16, 2020

Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership

Biogen earns top scores on areas including access to medicine, talent attraction, innovation management and climate performance and reporting In 2013 Biogen became the 1 st U.S. biotech company to appear on the DJSI World Index 2020 marks the 8 th consecutive year that Biogen was listed among top

November 3, 2020

Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020

Cambridge, Mass. – November 2, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a webcast of its prerecorded presentation related to its Alzheimer’s disease investigational therapy, aducanumab, as well as a live, virtual question and answer (Q&A) session at the upcoming CTAD 2020 digital

November 3, 2020

Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting

In Phase 2 LILAC study, BIIB059 demonstrated a statistically significant reduction in joint disease activity compared to placebo in systemic lupus erythematosus patients Positive results build on previously reported cutaneous lupus erythematosus data and underscore Biogen’s commitment to the lupus

October 30, 2020

European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and TOKYO, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd.

October 7, 2020

Biogen to Report Third Quarter 2020 Financial Results October 21, 2020

Cambridge, Mass. — Biogen Inc. (Nasdaq: BIIB) today announced it will report third quarter 2020 financial results Wednesday, October 21, 2020, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

October 6, 2020

Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)

INCHEON, South Korea and CAMBRIDGE, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for SB11, a proposed biosimilar referencing

September 22, 2020

Biogen to Webcast Prerecorded Encore Aducanumab Presentation and Live Q&A from AAN 2020 Science Highlights on September 23, 2020

Cambridge, Mass. – September 22, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a prerecorded webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, as well as a live, virtual question and answer (Q&A) session at the upcoming AAN 2020

September 14, 2020

Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health

After achieving carbon neutrality in 2014, Biogen further bolsters its action against climate change with the goal to become fossil fuel free by 2040 and initiates research collaborations with global leaders to help address the effects of fossil fuel-driven air pollution on health.

September 11, 2020

New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio

New data from ongoing Phase 3 study further define the effectiveness and improved GI tolerability of VUMERITY ® (diroximel fumarate) Real-world findings evaluate quality of life benefits associated with TYSABRI ® (natalizumab) when compared to Ocrevus ® (ocrelizumab ) Additional real-world findings